
U.S. Visa Sticker Shock: New $250 ‘Integrity Fee'
Many travelers applying for U.S. tourist visas should be prepared to pay at least an additional $250 for a new 'Integrity Fee.'
It's part of the recent budget law and hasn't been implemented yet, but the Department of Homeland is authorized to start charging this fiscal year. Starting in Fiscal Year 2026, which starts October 1, the Visa Integrity Fee will be adjusted annually for inflation.
It applies to travelers applying for non-immigrant visas, but people from the more than 40 Visa Waiver Program countries are not subject to the Visa Integrity Fee.
Travelers are eligible for reimbursement sometime after the visa expires as long as they don't overstay the visa expiration date by more than five days or engage in unauthorized work.
'There is no timeline for implementation of the fee or direction as to how the fee will be collected and refunded,' according to the U.S. Travel Association.
One issue: It may discourage travelers from visiting the U.S. because they would have to shell out $250 and wonder if they would ever get the reimbursement.
'This fee, which will be at least $250 and comes on top of existing visa fees, adds an unnecessary financial barrier for international visitors,' said Erik Hansen, US Travel's senior vice president, government relation affairs. 'Among the top deterrents to visiting the U.S. are cost and visa wait times. And the new visa integrity fee increases the upfront costs of visiting the U.S. 144%, while doing nothing to lower interview wait times. Even if it is technically reimbursable, the added complexity and cost will discourage visitors.'
$24 I-94 Fee
That's not all of the costly news for some international arrivals in the new law: The application fee for the I-94 arrival and departure record will rise to $24 from $6.
This fee will likely apply to travelers entering the U.S. by land, and to travelers from Visa Waiver Program countries.
This fee will also increase each year with inflation. Those exempt from filling out the form include American citizens, resident aliens, most Canadians, and aliens with immigration visas.
$40 ESTA Fee
The Electronic System for Travel Authorization (ESTA) fee is rising to $40 from the current $21. This will be paid by travelers who enter the U.S. from Visa Waiver Program countries at least through 2034.
These are the Visa Waiver Program countries, according to the U.S. Department of State:
U.S. Department of State
Visa Wait Times and Cost
A family of four from Brazil, which is not a visa waiver program country, would pay $1,876 in visa fees under the new pay structure to travel to the U.S., an increase of more than $1,100, according to the trade association.
'At a time when the U.S. should be focused on attracting more international visitors, especially ahead of global events like the World Cup and Summer Olympics, burdening them with higher fees and reducing funding for Brand USA is counterproductive,' Hansen said. 'We need smarter policies that enhance our global competitiveness, not ones that make the U.S. a less welcoming destination.'
Revenue Generators
Backers of the fees, however, see them as revenue generators.
For example, 20% of the I-94 fees are earmarked for the Land Border Inspection Fee account, 20% go to Customs & Border Protection, and 60% ends up in the Treasury Department general fund.
Regarding the ESTA fee, $10 goes to the Department of Homeland Security for cost recovery, $13 is funneled to the Treasury Department for Deficit Reduction, and $17 of the fee goes to the Travel Promotion Fund, which funds Brand USA.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
MEI Pharma (MEIP) Becomes the First and Only Publicly Traded LTC Holder on a National Exchange
MEI Pharma, Inc. (NASDAQ:MEIP) is one of the . On July 18, MEI Pharma, Inc. (NASDAQ:MEIP) announced securities purchase agreements for a private investment in public equity (PIPE) for the sale and purchase of 29,239,767 shares of common stock at a price of $3.42 per share. A modern pharmaceutical laboratory with research scientists working at their desks. The expected aggregate gross proceeds for the transaction come up to approximately $100 million before the exclusion of placement agent fees and other estimated offering expenses. MEI Pharma, Inc. (NASDAQ:MEIP) has plans to use all of the net proceeds for the launch of its treasury strategy focused on Litecoin. The transaction is thus a notable milestone for the company's long-term strategic plan, establishing MEI Pharma, Inc. (NASDAQ:MEIP) as the first and only publicly traded company to adopt Litecoin as a treasury reserve asset. Often referred to as 'silver to Bitcoin's gold,' Litecoin is a peer-to-peer cryptocurrency that Charlie Lee created in October 2011. The integration of Litecoin into its treasury operations has allowed MEI Pharma, Inc. (NASDAQ:MEIP) access to a decentralized monetary asset that complements its cash management framework. MEI Pharma, Inc. (NASDAQ:MEIP) is a pharmaceutical company that develops pharmaceutical compounds. Its programs include Voruciclib and ME-344. While we acknowledge the potential of MEIP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Earnings Preview: What to Expect From Ingersoll Rand's Report
Ingersoll Rand Inc. (IR), valued at a market cap of $34.5 billion, is a globally diversified provider of mission-critical flow creation products and industrial solutions. Headquartered in Davidson, North Carolina, the company operates through two key segments: Industrial Technologies and Services, and Precision and Science Technologies. IR is expected to release its Q2 2025 earnings after the market closes on Thursday, July 31. Ahead of this event, analysts project the company to report an adjusted EPS of $0.76, a decline of 5% from $0.80 per share reported in the year-ago quarter. The company has met or surpassed Wall Street's bottom-line estimates in three of the past four quarters, while missing the estimate on one occasion. More News from Barchart Warren Buffett's Berkshire Hathaway Earns $93,150 Every Hour from Coca-Cola Dividends Alone These Are the Highest Yielding Dividend Aristocrats Today (Entire List) OpenAI CEO Sam Altman Calls DeepSeek's Bluff: 'I Don't Think They Figured Out Something Way More Efficient' Markets move fast. Keep up by reading our FREE midday Barchart Brief newsletter for exclusive charts, analysis, and headlines. For fiscal 2025, analysts expect Ingersoll Rand to report an adjusted EPS of $3.22, marking an increase of 1.3% from $3.18 in fiscal 2024. In addition, its adjusted EPS is expected to grow 9.3% year-over-year to $3.52 in fiscal 2026. IR stock has crumbled 12.6% over the past 52 weeks, underperforming the S&P 500 Index's ($SPX) 13.6% gain and the Industrial Select Sector SPDR Fund's (XLI) 20.6% return during the same period. On May 1, Ingersoll Rand released its Q1 earnings, and its shares rose marginally. Its revenue rose 2.8% year-over-year to $1.7 billion, aided by recent acquisitions, but came in just below estimates. Moreover, adjusted net income declined 8.3% from the prior year to $293.2 million, also missing projections. Analysts' consensus view on IR is moderately optimistic, with a "Moderate Buy" rating overall. Among 14 analysts covering the stock, seven suggest a "Strong Buy" and seven recommend a "Hold" rating. Its mean price target of $93 represents a 8.7% premium to current price levels. On the date of publication, Kritika Sarmah did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16 minutes ago
- Yahoo
Morgan Stanley Reiterates a Buy Rating on AbbVie (ABBV) With a $250 PT
AbbVie Inc. (NYSE:ABBV) is one of the best long term low volatility stocks to buy now. On July 10, Morgan Stanley analyst Terrence Flynn reiterated a Buy rating on AbbVie Inc. (NYSE:ABBV) and set a price target of $250.00. A pharmacist handing out a pharmaceutical drug to a patient in a drug store or chemist. AbbVie Inc. (NYSE:ABBV) reported positive fiscal Q1 2025 results that support the optimistic outlook, with adjusted diluted EPS reaching $2.46, experiencing a 6.5% growth. The company also reported $13.343 billion in net revenue for the first quarter of 2025, reflecting an 8.4% growth on a reported basis or 9.8% on an operational basis. AbbVie Inc. (NYSE:ABBV) is a research-based pharmaceutical company that develops and sells products to treat chronic diseases in oncology, gastroenterology, rheumatology, dermatology, virology, and various other serious health conditions. While we acknowledge the potential of ABBV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey.